The Interventional Effects of Xuezhikang and Pravastatin on Serum NO, ET, HS-CRP, IL-1 and TNF-α in Simple Essential Hypertensive Patients
|School||Chongqing Medical University|
|Keywords||essential hypertension nitric oxide endothelin high sensitive C response protein tumour necrosis factor-alpha IL-1 pravastatin Xuezhikang|
Objective: To investigate impacts of Xuezhikang or pravastatin combined with antihypertensive drugs on serum NO,ET,hs-CRP,IL-1 and TNF-αin essential hypertensive (EH) patients.Methods: Thirty healthy individuals were enrolled as normal control. One hundred and fifty EH patients were enrolled into the study and randomly distributed into the antihypertensive drugs treatment group (ATH group, 50 cases), the pravastatin treatment group ( PRA group, 50 cases ) and the Xuezhikang treatment group ( XZK group, 50 cases ). Patients in the 3 groups were treated with routine antihypertensive drugs, in addition, pravastatin and Xuezhikang were given to PRA group and XZK group respectively. Serum NO,ET,hs-CRP,IL-1 and TNF-αwere detected before and after eight-week treatment.Results: Compared with healthy individuals,Serum NO decreased and ET,hs-CRP,IL-1,TNF-αincreased significantly in EH patients. One hundred and thirty EH patients finished the study including 42 cases in ATH group, 43 cases in PRA group and 45 cases in XZK group. After the treatment, Serum NO in PRA group and XZK group was significantly higher than in the ATH group (P<0.01). Serum ET,hs-CRP,IL-1 and TNF-αin PRA group and XZK group were obviously superior to that in the ATH group (P<0.01). No significant difference was found between the pravastatin group and the XZK group.Conclusions: Combined use of Xuezhikang or pravastatin could improve endothelial function and inhibit inflammatory response in EH patients with the blood pressure controlled by antihypertensive drugs, leading to benefits independent of pressure-lowering.